The Pediatric Infectious Disease Journal · 2023 · 13 citations · 17 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyBacteriologyMedical MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingCystic FibrosisMedical BacteriologyPulmonary InfectionsRespiratory Tract InfectionsBactericidal AgentsBacteriophage BiologyBacteriophage TherapyBacteriophagesDrug-resistant PathogensMultidrug-resistant OrganismsMultidrug-resistant PathogensPediatric Cystic Fibrosis Pharmacotherapy
BACKGROUND: Cystic fibrosis (CF) is a genetic disease associated with lung disease characterized by chronic pulmonary infection, increasingly caused by multiple drug-resistant pathogens after repeated antibiotic exposure, limiting antibiotic treatment options. Bacteriophages can provide a pathogen-specific bactericidal treatment used with antibiotics to improve microbiologic and clinical outcomes in CF. METHODS: Achromobacter species isolates from sputum of a chronically infected person with CF, were assessed for susceptibility to bacteriophages: 2 highly active, purified bacteriophages were administered intravenously every 8 hours, in conjunction with a 14-day piperacillin/tazobactam course for CF exacerbation. Sputum and blood were collected for metagenome analysis during treatment, with sputum analysis at 1-month follow-up. Assessments of clinical status, pulmonary status and laboratory evaluation for safety were conducted. RESULTS: Bacteriophage administration was well-tolerated, with no associated clinical or laboratory adverse events. Metagenome analysis documented an 86% decrease in the relative proportion of Achromobacter DNA sequence reads in sputum and a 92% decrease in blood, compared with other bacterial DNA reads, comparing pretreatment and posttreatment samples. Bacteriophage DNA reads were detected in sputum after intravenous administration during treatment, and at 1-month follow-up. Reversal of antibiotic resistance to multiple antibiotics occurred in some isolates during treatment. Stabilization of lung function was documented at 1-month follow-up. CONCLUSIONS: Bacteriophage/antibiotic treatment decreased the host pulmonary bacterial burden for Achromobacter assessed by metagenome analysis of sputum and blood, with ongoing bacteriophage replication documented in sputum at 1-month follow-up. Prospective controlled studies are needed to define the dose, route of administration and duration of bacteriophage therapy for both acute and chronic infection in CF.
17
Robert T. Schooley, Biswajit Biswas, Jason J. Gill et al. · Antimicrobial Agents and Chemotherapy · 2017 · 1.3K citations · Full text
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Benjamin K. Chan, Mark Sistrom, John E. Wertz et al. · Scientific Reports · 2016 · 722 citations · Full text
Saima Aslam, Elizabeth Lampley, Darcy Wooten et al. · Open Forum Infectious Diseases · 2020 · 335 citations · Full text